spacer
home > ebr > > proteolytic enzymes as therapeutic targets
PUBLICATIONS
European Biopharmaceutical Review

Proteolytic Enzymes as Therapeutic Targets

The regulation of protein secretion is central to the proper functioning of eukaryotic organisms. One mode of protein secretion is the generation of soluble fragments of membrane-bound proteins by limited proteolysis through the action of proteases termed secretases, or sheddases. In general, cleavage occurs close to the extracellular face of the membrane, releasing active protein. Proteins secreted in this fashion include some membrane receptors and receptor ligands, ectoenzymes and cell adhesion molecules. Since the proteins concerned are involved in pathophysiological processes, such as neurodegeneration, inflammation and oncogenesis, inhibitors of respective secretases are emerging as promising therapeutic drugs. This article will review a number of methods that have allowed molecular cloning of secretases and discuss different approaches to discovering specific secretase inhibitors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Urs Lüthi, Senior Scientist at ESBATech

Dr Urs Lüthi carried out his PhD studies at ESBATech under the supervision of Dr Alcide Barberis and has recently completed his dissertation on the subject of functional screening systems in yeast to identify secretases, targets of secretases and modulators of secretase activity. An essential part of his work focused on the development of the cellular assay for BACE activity that is further developed for small compound inhibitors screens.
He will continue to develop his expertise as a Senior Scientist with ESBATech and will be responsible for the development of similar cell-based assay systems. Urs' academic work was presented at several international conferences and published in peer-reviewed journals.

spacer
Dr Urs Lüthi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

DrugDev Named Best Place to Work by the Philadelphia Business Journal as Company Continues to Seek Talented Individuals to Join its Expanding Team

AUDUBON, Pa. and LONDON — The Philadelphia Business Journal has named DrugDev one of its Best Places to Work in the Philadelphia region. The recognition continues the tradition established by CFS Clinical – the leading provider of global investigator payment, contracting and regulatory services - which had been named to the prestigious list each of the previous two years until it was acquired by DrugDev in October 2013.
More info >>

White Papers

Working Towards a Standardised Identification Solution

Packaging Coordinators, Inc.

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

Orphan Drugs and Rare Diseases

20-21 October 2014, Holiday Inn Regents Park Hotel, London, UK

As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and theEarly Access to Medicines Scheme was introduced. Key implementation of this will be a factor into further commercialisation and developments.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement